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Brain-derived neurotrophic factor (BDNF) has several functions in the central nervous system, where it contributes to brain
development and its functionality through affecting neuronal survival and activity and also modulating neurotransmitter levels.
This neurotrophin is also found in the serum, but its origin and peripheral function remain unknown. Although the source of
circulating BDNF is uncertain, it is stored in platelets and can be released through pharmacological treatment. Decreased levels of
BDNF in the serum have been related to the pathophysiology of depression, and this relationship is reinforced by the reversal of this
condition by treatment with antidepressants. Recently, riluzole has been proposed for the treatment of depression because it has
the ability to lower extracellular glutamate levels and increase BDNF expression; and both mechanisms could be associated with its
antidepressant action. Considering that riluzole enhances BDNF levels in the serum of patients, we investigated if treatment with
this drug could stimulate the release of this neurotrophin from human platelets obtained from healthy subjects. When platelets
were incubated with riluzole for 4 h, the basal value of BDNF (92.9 ± 11.1 pg 10−6 platelets) was significantly increased (𝑃 < 0.05,
𝑛 = 27). This stimulatory effect was achieved at low concentrations of riluzole (from 10𝜇M) and was not observed when platelets
were incubated with the drug for 24 h. The direct action of riluzole evoking BDNF release from human platelets at therapeutic
concentrations is important and may contribute to the understanding of its mechanisms of action in the treatment of depression.
1. Introduction
Brain-derived neurotrophic factor (BDNF) contributes to
brain development [1, 2] and is related to neuronal survival
and activity since it acts as a modulator of neurotransmitter
levels and participates in neuronal plasticity [3, 4]. In the
human, monkey, and rat, BDNF is also found in the serum
at significant levels [5–7], but the origin and function of
this neurotrophin remain unknown. Investigators have men-
tioned the brain as the source for this circulating neurotro-
phin [8], even though it has been demonstrated that BDNF
crosses the blood-brain barrier (BBB) in both directions
[9, 10]. Indeed, BDNF may originate from neurons and glia
cells [9, 10]; however, it is also released at significant rates
by other peripheral tissues, such as different epithelia, where
its amounts may reach levels higher than those found in
the central nervous system (CNS) [11]. Other examples of
BDNF origins other than from CNS are white cells [12–
14] and platelets; the latter contain significant quantities of
this protein and might provide an important source of this
circulating neurotrophin [5]. It has been shown that more
than 99% of blood BDNF proteins are stored in platelets and
that these proteins can be released into the serum [6] through
pharmacological treatment [15, 16].
Recent studies have reported changes in serum BDNF
levels in patients with psychiatric diseases [17–20], such as
major depressive disorders [21]. The relationship between
decreased BDNF levels and the pathophysiology of depres-
sion is supported by several reports [21–25]. Pandey et al. [26]
showed that gene expression of BDNF in lymphocytes and
its protein expression in platelets from adult and pediatric
depressed patients were significantly decreased, and the
authors proposed that it could be a target for antidepressant
drugs. In fact, some antidepressants increase BDNF expres-
sion [27] and also may evoke BDNF release from platelets,
in a dose-dependent manner after direct treatment in vitro
[15]. The BDNF concentration in the serum increases after
intravenous treatment with an antidepressant, and the effect
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of these drugs on BDNF release from platelets was related to
the level of this neurotrophin in the peripheral blood [15].
Recently, glutamatergic modulators have been proposed
as a strategy for the treatment ofmood disorders [28]. Among
the drugs proposed is riluzole (2-amino-6-trifluoromethoxy
benzothiazole), which was originally developed as an anti-
convulsant [29] but has been used in a number of trials for
psychiatric conditions in which glutamate excess has been
proposed as part of the pathologic mechanism [30–33]. Dif-
ferent mechanisms of action have been reported for riluzole
[32], which probably explains its complex pharmacological
effects. For instance, a stimulatory effect on glutamate uptake
was observed at low glutamate concentration [34], and this
ability to lower extracellular glutamate levels was suggested as
its mechanism of antidepressant action, at least partially [32].
However, other mechanisms cannot be ruled out, since rilu-
zole also increases the BDNF expression [35, 36], which could
also contribute to its antidepressant action [32]. Treatment
with riluzole significantly increases serum levels of BDNF in
patients [37]. Considering that BDNF in the blood is thought
to originate from platelets and is evoked by antidepressant
drugs, we decided to investigate if riluzole could stimulate the
release of this neurotrophin from human platelets.
2. Methods
2.1. Subjects. Human blood was collected from 27 healthy
male volunteers registered as donors in the Hemotherapy
Service of the Clinical Hospital of Porto Alegre, Rio Grande
do Sul, Brazil. The study was carried out in accordance
with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.
Informed consent was obtained from the donors and their
privacy rights were observed.
2.2. Procedures. Two samples of 4mL were taken from the
antecubital vein of each donor and placed in vacutainers
(BD Franklin Lakes, USA) containing K
3
-EDTA. Immedi-
ately, they were gently inverted 10 times and placed in an
ABX Micros ES 60 hematology analyzer (HORIBA ABX
SAS, Japan) to determine the number of platelets in each
blood sample. Platelets were isolated as previously described
by Mangano and Schwarcz [38]. The vacutainers were then
centrifuged at 300×g for 5min at 4∘C and the platelet-rich
plasma (PRP) was obtained.The supernatant (PRP) was care-
fully removed with a plastic pipette tip, with care not to
disturb the leukocyte layer.The volume of PRP collected from
each sample was recorded and the PRP was transferred to
a microcentrifuge tube. The PRP was then centrifuged at
7000×g for 10min at 4∘C. The plasma was discarded and
the pellet was resuspended in 0.5mL of 0.32M phosphate-
buffered sucrose (pH 7.4 at 4∘C). The suspension, hereafter
referred to as the platelet concentrate (PC), was repeatedly
passed through a plastic pipette tip of 1mL until the visible
platelet aggregates were eliminated. An additional 0.5mL
of buffered sucrose was added to the suspension and the
solutionwasmixedwith 5 gentle inversions.ThePCwas again
centrifuged at 7000×g for 5min at 4∘C.The supernatant was
discarded, and the pellet was resuspended in a volume of
0.32M phosphate-buffered sucrose (pH 7.4 at 4∘C), equal to
one-fifth of the initial volume of PRP obtained. After that,
the two PC suspensions obtained from each subject were
blended and the number of platelets was determined again.
As previously observed by our group, the platelets should
be counted in the PC, after the platelets are washed [39].
The mean platelet volume (MPV) and platelet distribution
width (PDW) were also determined in both the whole blood
and the PC to evaluate potential variations in the platelets
during the processing. The incubation was performed in a
96-well plate; to each well were added 20 × 106 platelets in










Tris-HCl, and 10.2mM glucose), pH 6.5. Drugs were diluted
in Tris-citrate buffer, and the final volume in the well was
150 𝜇L.
2.3. BDNF Protein Assay. BDNF levels in the supernatants
were measured using a ChemiKine Brain Derived Neuro-
trophic Factor Sandwich ELISA kit (Millipore, USA) follow-
ing themanufacturer’s instructions. All BDNFmeasurements
were performed in triplicate on 96-well plates, and a standard
curve was calculated for each experiment. Samples from the
supernatants were diluted 1 : 16 in phosphate buffer solution
(pH 7.4) for BDNFmeasurement. The platelet BDNF content
was calculated by dividing the result for BDNF obtained by
the total platelet count from the same individual and was
expressed as pg BDNF 10−6 platelets. The optical density of
each well was measured using a microplate reader (EZ Read
400, Biochrom, UK) set to 450 nm; the optical densitometry
data were analyzed with the software Galapagos (Biochrom,
UK). The sensitivity was 7.8 pg BDNFmL−1 and the assay
exhibited no cross-reactivitywith othermembers of the nerve
growth factor family.
2.4. MTT Assay. The MTT assay was utilized to determine
the effect of riluzole or sertraline on platelet viability after
4 or 24 h of drug exposure. For shorter incubation times
(4 h), 20𝜇L MTT (5mgmL−1) was added to each well at the
time that the platelets were plated, and it was maintained at
room temperature by 4 h. For longer incubation times (24 h),
20𝜇L MTT (5mgmL−1) was added to each well 20 h after
plating andmaintained at room temperature for an additional
4 h. Subsequently, 150 𝜇L of DMSO was added to dissolve
the formazan, which was detected using a microplate reader
(EZ Read 400, Biochrom, UK). The absorption was read at
570 nm; the value obtained (UAbs) was expressed as UAbs
20 ⋅ 10
−6 platelets.
2.5. Statistical Methods. Values are reported as mean ± SEM,
and the statistical analysis was conducted using SPSS. The
data were normally distributed, as determined by the Shap-
iro-Wilk normality test, and were analyzed through one-
way ANOVA (for BDNF) or two-way ANOVA (for MTT)
followed by Tukey’s multiple comparisons test (alpha at 0.05).





















Figure 1: Scatter plot of BDNF released from human platelets. The mean of BDNF values (92.9 ± 11.1 pg 10−6 platelets) is indicated by the

























Figure 2: Stimulatory effect of riluzole on BDNF release. Platelets obtained from healthy donors were incubated with different concentrations
of riluzole (1, 10, 40, or 100𝜇M) for 4 h. Control is represented by the dotted line. Data are presented as mean ± SEM. ∗Different from control
(𝑛 = 27, 𝑃 < 0.05).
3. Results
We used washed platelets to test if riluzole could stimulate
BDNF release, acting directly on these cells. Initially, the
platelet indices (cell count, MPV, and PDW) were measured
in whole blood and again after obtaining the PC, to evaluate
if these parameters changed during the processing. Then, the
platelet number quantified in each PC was used to normalize
the BDNF quantity in the respective experiment. Our data
showed that the platelet count should be determined after the
PC is obtained, since the cell number was reduced during the
process (yield of 42 ± 8%). Analysis of PC showed an absence
of contaminant cells; and despite the loss of platelets, the
MPV and PDW indices were not changed after the cells were
obtained. The platelet indices MPV and PDW in the whole
blood were 8.1±0.6 𝜇m3 and 14.9±1.0%, respectively. When
compared with PC, we did not observe significant differences
for MPV and PDW, which showed levels of 8.2± 0.6 𝜇m3 and
15.5 ± 1.2%, respectively. In our analysis, the platelet number
achieved in the PC was 1545 ± 338 × 103mm−3.
In our experimental conditions, the basal values of
BDNF released from platelets of donors ranged from 9.0 to
220.2 pg 10−6 platelets. The wide distribution of BDNF quan-
tified in the study group is depicted in Figure 1.
Given the recent evidence that riluzole treatment causes
a significant increase of BDNF in the serum of patients [37],
the effect of this drug on BDNF release from human platelets
was tested. Platelets fromhealthy volunteerswere treatedwith
different concentrations of riluzole for 4 or 24 h at room
temperature. When platelets were incubated with riluzole for
4 h, the basal value of BDNF as quantified from the controls
(92.9±11.1 pg 10−6 platelets) was significantly increased (𝑃 <
0.05). Even for platelets from donors who showed lower basal
levels of BDNF, treatment with riluzole stimulated the release
of this neurotrophin. The increase mediated by riluzole was
significant beginning with 10𝜇M (15%) and was maintained
up to 40 𝜇M (22%) and 100 𝜇M (20%). We also tested the
effect of 1 𝜇M riluzole, which did not differ from the control
(Figure 2).
The effect of riluzole on the BDNF release determined in
our model was reproducible in repeated runs, even though
it varied from individual to individual. Considering this
variability in the basal levels of BDNF among different donors
(Figure 1), in each set of experiments, the drug effect was


























Figure 3: Platelet viability during the incubation period.The effect of different concentrations of riluzole on platelet viability was determined
at 4 or 24 h of incubation. No significant differences were observed among the groups. Data are presented as mean ± SEM (𝑛 = 27).
compared with the respective control.We also used sertraline
(0.3 𝜇M) as a positive control, since it was recently reported
to be a potent inducer of BDNF release from platelets [15].
However, contrary to expectations, in our experiments, the
sertraline did not significantly stimulate BDNF release (data
not shown).
The increase in the release of BDNF evoked by riluzole
was not observedwhenplateletswere incubatedwith the drug
for 24 h. In order to determine if platelet viability was affected
by riluzole during the exposure, we used the MTT assay.
Hence, the activity of NAD(P)H-dependent cellular oxidore-
ductase enzymes was evaluated after 4 and 24 h incubation.
The viability of the untreated platelets did not differ after the
two incubation periods, although slightly less formazan was
produced after 24 h (Figure 3).
4. Discussion
We evaluated the platelet parameters MPV and PDW, since
these indices have been reported to correlate with platelet
function [40]. MPV is a measurement that is commonly
used to describe platelet size and is an indicator of activated
platelets [41, 42], while PDW represents the range of vari-
ability in platelet volume [43]. Taking into account that MPV
and PDW did not change before the platelets were obtained
and after they were processed, we can state that the platelets
used in this study were not activated at the time of exposure
to riluzole. Importantly, we did not select a subpopulation of
these cells, since no significant difference was observed in the
PDW. Another important point is that our protocol used only
platelets, and, consequently, the BDNF quantified cannot be
attributed to contaminant cells such as leukocytes.
In our study, we observed a direct action of riluzole, evok-
ing BDNF release from human platelets. The stimulatory
effect was achieved at low concentrations (from 10 𝜇M),
which could be important information for the clinical use
of riluzole. Although this increase was not as large as found
for another antidepressant [15], the stimulatory effect was
reproducible when compared with the respective controls,
despite the variations among different donors. The absence
of a sertraline effect on BDNF release might be due to our use
of human cells, whereasWatanabe et al. [15] used rat platelets.
Unfortunately, Watanabe and coauthors did not report the
basal values of BDNF that they obtained, which would allow
comparison with our data.
Riluzole evoked an acute effect on the platelets, which
was not observed after longer incubation times.The release of
BDNF in response to riluzole acutely (4 h) and not later (24 h)
suggests that its effect derived from evoking neurotrophin
release from the platelet pool and is not related to a stimu-
latory effect on neurotrophin synthesis. This is in accordance
with data showing thatmRNA expression of BDNF in human
platelets is extremely low [5, 10].
The novel finding that riluzole elicits BDNF release from
human platelets is important, since this situation may occur
peripherally and also in deep regions of the CNS, where
platelets and astrocytes are very close and where this neu-
rotrophin is able to pass through the BBB. Beyond the periph-
eral consequences of this release mediated by riluzole, the
effects of this neurotrophin on the CNS may be complex and
significant, especially regarding the glutamatergic system. It
has been shown that BDNF exerts acute effects on glutamater-
gic synaptic transmission and plasticity, that is, enhancing
excitatory synaptic transmission throughpre- andpostsynap-
ticmechanisms [44]. On the other hand, its stimulatory effect
on the expression of astroglial glutamate transporters and the
consequent increase in glutamate uptake capacity has also
been described [45]. More recently, it was demonstrated that
BDNFupregulates the protein expression of the vesicular glu-
tamate transporters (VGLUT1 andVGLUT2) in hippocampal
neurons [46], which reinforces the participation of BDNF as
a modulator of the glutamatergic synapse.
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Clinically, riluzole has been used in trials for psychiatric
conditions where glutamate excess is proposed as part of the
pathologic mechanism [47]. It is also suggested that it pro-
duces antidepressant and anxiolytic effects in the treatment
of resistant depression [32]. Its effect in these conditions is
associated with the ability to reduce extracellular glutamate
levels and also may involve its stimulatory action on BDNF
expression [32]. Therefore, the demonstration that riluzole
causes BDNF release at low concentrations is significant in
vivo and shows the importance of studying platelets from
patients treated with this drug. Studies to clarify the mech-
anisms related to BDNF release in human platelets are cur-
rently in progress in our laboratory.
5. Conclusions
The new effect described for riluzole may contribute to the
understanding of themechanisms involvedwith its therapeu-
tic action, reinforcing the suggestion for its use in psychiatry,
such as in the treatment of depression.
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